Journal
ANNALS OF HEMATOLOGY
Volume 89, Issue 6, Pages 613-618Publisher
SPRINGER
DOI: 10.1007/s00277-009-0885-5
Keywords
CTLA-4 polymorphism; Transplant outcome; Survival; Disease relapse
Categories
Funding
- Ministero dell'Istruzione, dell'Universit e della Ricerca
- Regione Liguria
Ask authors/readers for more resources
Conflicting observations have been reported about the role of CTLA-4 gene polymorphisms in the clinical outcome of allogeneic hematopoietic stem cell transplantation (HSCT). We have investigated three polymorphisms of the CTLA-4 gene (-318C > T, +49A > G, CT60G > A) in 133 donor/recipient pairs who underwent HLA-matched sibling donor HSCT for hematological malignancies. We found no association of the clinical outcome of the HSCT with either recipient or donor -318C > T and CT60G > A polymorphisms. At variance, we found a significant association of donor +49A > G G/G genotype with longer overall survival (OS; log-rank test, P = 0.04), and the number of +49A > G G-alleles in the recipient with longer OS (P = 0.027), longer disease-free survival (P = 0.036) and reduced relapse rate (P = 0.042). However, only recipient +49A > G polymorphism was retained as independent prognostic factor in a multivariate analysis, suggesting that the expression of CTLA-4 on the cells of recipient may be relevant for the clinical outcome of HSCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available